Cognetivity Neurosciences Past Earnings Performance
Past criteria checks 0/6
Cognetivity Neurosciences's earnings have been declining at an average annual rate of -29.7%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 96.5% per year.
Key information
-29.7%
Earnings growth rate
-12.5%
EPS growth rate
Medical Equipment Industry Growth | 4.3% |
Revenue growth rate | 96.5% |
Return on equity | n/a |
Net Margin | -8,732.8% |
Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cognetivity Neurosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Oct 23 | 0 | -9 | 3 | 0 |
31 Jul 23 | 0 | -8 | 3 | 1 |
30 Apr 23 | 0 | -8 | 3 | 1 |
31 Jan 23 | 0 | -7 | 4 | 1 |
31 Oct 22 | 0 | -10 | 6 | 1 |
31 Jul 22 | 0 | -14 | 9 | 0 |
30 Apr 22 | 0 | -14 | 9 | 0 |
31 Jan 22 | 0 | -13 | 8 | 0 |
31 Oct 21 | 0 | -9 | 5 | 1 |
31 Jul 21 | 0 | -3 | 2 | 1 |
30 Apr 21 | 0 | -3 | 2 | 1 |
31 Jan 21 | 0 | -2 | 1 | 0 |
31 Oct 20 | 0 | -1 | 1 | 0 |
31 Jul 20 | 0 | -2 | 1 | 0 |
30 Apr 20 | 0 | -2 | 1 | 0 |
31 Jan 20 | 0 | -3 | 2 | 0 |
31 Oct 19 | 0 | -3 | 2 | 1 |
31 Jul 19 | 0 | -3 | 2 | 1 |
30 Apr 19 | 0 | -3 | 2 | 1 |
31 Jan 19 | 0 | -4 | 3 | 1 |
31 Oct 18 | 0 | -4 | 2 | 1 |
31 Jul 18 | 0 | -4 | 2 | 1 |
30 Apr 18 | 0 | -3 | 2 | 0 |
31 Jan 18 | 0 | -1 | 1 | 0 |
31 Oct 17 | 0 | -1 | 0 | 0 |
31 Jan 17 | 0 | 0 | 0 | 0 |
Quality Earnings: 1UB is currently unprofitable.
Growing Profit Margin: 1UB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1UB is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.
Accelerating Growth: Unable to compare 1UB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1UB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).
Return on Equity
High ROE: 1UB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.